159 results about "Staphylococcus epidermidis" patented technology

The invention relates to Penicillium decumbens C01 and application of the Penicillium decumbens C01, and belongs to the technical field of microorganisms. The penicillium decumbens C01 disclosed by the invention is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number of the penicillium decumbens C01 is GDMCC NO.66456. The strain is obtained by separating, purifying and screening soil samples collected from botanical gardens in South China of Guangzhou; tests show that the bacteriostatic active substance generated by fermentation of the strain has a good bacteriostatic effect on staphylococcus epidermidis, staphylococcus aureus, escherichia coli, propionibacterium acnes, candida albicans and pseudomonas aeruginosa, and the bacteriostatic active substance has the characteristic of high temperature resistance and excellent preservative effect; the antibacterial preservative can be used as an antibacterial preservative raw material, is applied to the fields of food, health care products or daily chemical products and the like, and has wide application prospects and important conversion research values.

The invention belongs to the technical field of polypeptide drugs in biochemistry, and discloses three antibacterial peptide analogues as well as a preparation method and application thereof, the sequence of an antibacterial peptide P-1 is CH3CO-GGGENIKKILSKIKLLK-NH2, the sequence of an antibacterial peptide P-2 is CH3CH2CH2CO-GGGENIKKILSKIKLLK-NH2, the sequence of an antibacterial peptide P-3 is CH3 (CH2) 6CO-GGGENIKKILSKIKLLK-NH2, the carboxyl ends of polypeptides are subjected to amidation, and the polypeptides are all positively charged when the pH is equal to 7. The artificially synthesized antibacterial peptide disclosed by the invention shows a remarkable sterilization effect on multidrug resistant staphylococcus epidermidis. P-1, P-2 and P-3 have small molecular weight, are convenient to synthesize, have broad-spectrum bactericidal activity, are self-assembled into nanoparticles, have low cytotoxicity, resist trypsin degradation and the like, and have wide application prospects.

The invention discloses glucoside hydrolase with anti-biofilm activity and application of the glucoside hydrolase. Experiments prove that the PgaBAb1 protein and the PgaBKp protein have remarkable anti-staphylococcus epidermidis biofilm activity and can destroy a mature staphylococcus epidermidis biofilm and inhibit formation of the staphylococcus epidermidis biofilm, that is, the PgaBAb1 protein and the PgaBKp protein are glucoside hydrolase with anti-biofilm activity; meanwhile, the sensitivity of the staphylococcus epidermidis to methicillin can be improved; the amino acid sequences of the PgaBAb1 protein and the PgaBKp protein are respectively as shown in SEQ ID NO: 5 and SEQ ID NO: 6. Therefore, both the PgaBAb1 protein and the PgaBKp protein can be used as active ingredients of drugs to treat diseases caused by infection of bacteria generating biological membranes and / or drug-resistant bacteria. The method has an important application value.

The invention discloses a breast milk-derived staphylococcus epidermidis strain and application thereof. The invention provides a staphylococcus epidermidis strain, and the preservation number of the staphylococcus epidermidis strain is CGMCC (China General Microbiological Culture Collection Center) No.31507. The staphylococcus epidermidis strain has the advantages that the staphylococcus epidermidis strain can be used for preparing the staphylococcus epidermidis strain; the strain of the staphylococcus epidermidis, provided by the invention, has good intestinal adaptive capacity, safety and stability, and can be used for inhibiting enteropathogenic bacteria and improving the immune response reaction of host immune cells.

The invention relates to the field of plant extracts, and discloses a plant composition for regulating scalp micro-ecological balance and application thereof. The plant composition disclosed by the invention takes extracts of leontopodium alpinum and birch bark as active ingredients, has the characteristics of effectively inhibiting staphylococcus aureus and restrictive malassezia and not influencing normal proliferation of staphylococcus epidermidis, so that the plant composition can be used for regulating scalp micro-ecological balance, regulating and controlling scalp microbial flora in a targeted manner and improving scalp microecological balance. Therefore, the scalp grease secretion is reduced, and the scalp problems such as dandruff, scalp itching, scalp papule, allergy and redness, exuberant grease secretion and the like are relieved.

The present invention relates to the use of a combination of a saccharide and glycerol for skin protection against undesirable bacteria. The present invention is particularly useful in the formulation of compositions that act as prebiotics for commensal skin bacteria such as S. epidermidis to produce metabolites such as lactic acid, which, through the present invention, has been shown to inhibit the growth of undesirable bacteria such as E. coli and S. aureus, among others. The present invention is especially useful because it provides both short-term (i.e., rapid) and long-term (or sustained) protection.

The invention discloses a multiple qPCR (quantitative polymerase chain reaction) detection reagent for detecting neonatal gastrointestinal infection pathogens. The kit comprises specific primers and probes for detecting enterohemorrhagic escherichia coli, staphylococcus aureus, pseudomonas aeruginosa, streptococcus agalactiae, klebsiella pneumoniae, staphylococcus epidermidis, beta hemolytic streptococcus, salmonella, rotavirus and adenovirus. According to the invention, different fluorescently-labeled probes are utilized to add specific primers and probes of multiple pathogens into a reaction system to detect multiple targets at the same time, and the method has the advantages of good specificity, high sensitivity, short detection period, capability of simultaneously detecting multiple pathogens, rapidness, simplicity, convenience and economy; a convenient method is provided for rapid detection of pathogens causing neonatal gastrointestinal infection, and the kit has important significance in epidemiological research, clinical early molecular diagnosis and the like.

The present application relates to a strain of Penicillium decumbens (P. Penicillium decumbens ) C01 and its application, and belongs to the field of microbial technology. The Penicillium decumbens C01 disclosed by the present application has been preserved in the Guangdong Microbial Digital Culture Collection Center, and its preservation number is GDMCC NO.66456. The strain is isolated, purified and screened from a soil sample collected in the garden area of Guangzhou South China Botanical Garden. Tests show that the bacteriostatic active substance produced by fermentation of the strain has good bacteriostatic effect on Staphylococcus epidermidis, Staphylococcus aureus, Escherichia coli, Propionibacterium acnes, Candida albicans and Pseudomonas aeruginosa. Moreover, the bacteriostatic active substance has high-temperature resistance and excellent preservative effect, and can be used as a bacteriostatic and preservative raw material, applied in the fields of food, health care products or daily chemical products, and has broad application prospect and important transformation research value.

The invention discloses a mild antibacterial anti-dandruff composition and a preparation method thereof. The composition comprises an acrylate copolymer, maltooligosaccharide and bisabolol, the mass ratio of the acrylate copolymer to the maltooligosaccharide to the bisabolol is (0.01 to 0.3) to (0.1 to 0.8) to (0.05 to 0.5); the preparation method comprises the following steps: sequentially adding the acrylate copolymer, the maltooligosaccharide and the bisabolol into water according to the mass ratio, and uniformly stirring until the materials are dissolved. The acrylate copolymer, the maltooligosaccharide and the bisabolol are blended in proportion, the maltooligosaccharide becomes a carbon source of microorganisms, malassezia is efficiently inhibited, staphylococcus epidermidis is not excessively inhibited, and meanwhile, the skin mildness and moisture retention are achieved; the bisabolol is used as a plasticizer, so that the composition of the acrylate copolymer and the maltooligosaccharide forms a uniform and tough film, the effect on malassezia and staphylococcus epidermidis is enhanced, and the anti-dandruff effect is improved.

The application discloses a fabric yellowing reagent and a fabric yellowing method, and relates to the technical field of daily chemical products. 5 The fabric yellowing reagent comprises 1-3% of histidine solution and a bacterial suspension with a bacterial concentration of 1*10 5 CFU / mL-9*10 The bacteria are a mixture of one or more of Staphylococcus epidermidis and Micrococcus luteus; the solvent of the histidine solution is normal saline containing 0.15-1% of trypsin peptone; and the solvent of the bacterial suspension is normal saline containing 0.1-0.2% of trypsin soybean peptone liquid culture medium. The fabric yellowing reagent can be used for simulating fabric yellowing, and has good operability, reproducibility and data reliability.

The invention provides bacillus mojavensis and belongs to the technical field of microorganisms. The preservation number of the bacillus mojavensis VT275 is CGMCC (China General Microbiological Culture Collection Center) No.29974. The bacillus mojavensis VT275 can be used for effectively inhibiting common skin pathogenic bacteria and food-borne pathogenic bacteria, such as staphylococcus aureus, methicillin-resistant staphylococcus aureus, staphylococcus epidermidis, listeria monocytogenes, shigella, enterococcus faecalis and the like. The bacillus mojavensis VT275 disclosed by the invention can be used for preventing or treating skin diseases such as specific dermatitis or controlling food-borne infection, and has a good application prospect in the fields of medicines, cosmetics, edible microorganisms, feed microorganisms and the like.

The invention relates to a biomarker for individual recognition and application thereof, and relates to the technical field of biology. The biomarker comprises at least one of the following microorganisms: propionibacterium acnes, staphylococcus epidermidis, marine paracoccus, streptococcus, rhodococcus fence celebrating, staphylococcus, pseudomonas, streptococcus sanguineus, achromobacter xylosoxidans, acinetobacter calcoaceticus, acinetobacter johnsonii, staphylococcus lentus, pseudomonas toralaris and brevundimonas vesicularis. Or enterococcus faecium. The biomarker can provide analysis with higher resolution in the aspect of differential strain information, has a better distinguishing effect, higher accuracy and sensitivity on individual recognition, and can be used as a new technical means for supplementing forensic individual recognition.

The present invention relates to the field of biological fermentation application technology, and in particular, to use of a milk peptide fermentation product in regulating skin microecological balance. The milk peptide fermentation product selectively regulates the growth of Staphylococcus epidermidis and inhibits the growth of Staphylococcus aureus and Escherichia coli. It was discovered for the first time that the milk peptide fermentation product has a selective bacteriostatic effect on skin microorganisms. The experimental results show that the milk peptide fermentation product has an inhibitory effect on Escherichia coli and Staphylococcus aureus, but has no effect on the normal growth of Staphylococcus epidermidis. This characteristic is obviously different from common broad-spectrum chemical bacteriostatic agents, and the use of the milk peptide fermentation product is more conducive to maintaining the balance of skin microbiota.

The invention provides an application of GSK2018682 in preparation of a medicine for resisting gram-positive bacterial infection, and the GSK2018682 has a CAS number of 1034688-30-6. The invention also provides an application of the GSK2018682 in preparation of a medicine for resisting gram-positive bacterial infection. According to the technical scheme, the novel medical application of the GSK2018682 is disclosed, and the GSK2018682 has good antibacterial activity and anti-biofilm activity on various gram-positive bacteria and can inhibit growth of staphylococcus aureus, staphylococcus epidermidis, enterococcus faecalis, enterococcus faecium and the like and formation of biofilms.

The present disclosure provides recombinant Staphylococcus bacterium (e.g. S. epidermidis) that are dependent on D-alanine for growth. In one aspect, the disclosure features a recombinant Staphylococcus bacterium comprising two inactivated alanine racemase genes (Δalr1 Δalr2); and an inactivated D-alanine aminotransferase (dat) gene. In another aspect, the disclosure features a method of making the recombinant Staphylococcus bacterium. In another aspect, the disclosure features a method of treating or preventing a rash in a subject, comprising administering to the subject a population of the recombinant Staphylococcus bacterium of any one of the aspects or embodiments described herein, in an effective amount to treat or prevent the rash in the subject.

The present invention belongs to the technical field of skin care, and discloses a lipid regulation promoting composition, application and skin care product, wherein the lipid regulation promoting composition comprises 0.1-2.4 parts of natural vegetable oil and 0.1-2.4 parts of potassium salt by weight. The present invention adopts natural vegetable oil and potassium salt to compound and synergistically activate Staphylococcus epidermidis on the surface of the skin, thereby promoting the related lipase to strengthen and promote the expression of saturated fatty acids, promoting the skin to regulate the lipid component structure, and effectively avoiding the damage of the skin barrier.

The present invention relates to topical formulations comprising a combination of antimicrobial peptides (AMP), in particular synthetic cyclic peptide compounds based on thiazolidine and # imgabs0 # oxazolidine components, and a skin soothing substance, such as menthoxypropanediol, a substance that enhances the skin barrier, such as omega-6 fatty acids, and / or a flavonoid, such as licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone. In particular, the present invention relates to compounds that synergistically and selectively fight against pathogenic bacteria, such as Staphylococcus aureus (S. aureus) and Propionibacterium acnes (C. acnes), but not fight against skin symbiotic bacteria, such as Staphylococcus epidermidis (S. epidermidis). The formulations can be advantageously used in the treatment of acne or atopic dermatitis, as well as in the care of skin that has been impaired by acne or atopic dermatitis.

The invention provides a beta-diketoamide compound and application thereof in preparation of a gram infection resistant drug, the structural formula of the beta-diketoamide compound is as shown in formula (1), in the formula (1), R1 is H or halogen; r2 is nitro, alkyl, halogen or methoxyl. The beta-diketoamide compound disclosed by the invention comprises gram-positive bacteria such as staphylococcus aureus, enterococcus faecalis, enterococcus faecium and staphylococcus epidermidis and other clinical isolates, and shows antibacterial activity; after being combined with polymyxin, the compound has synergistic bacteriostatic activity on gram-negative bacteria such as acinetobacter baumannii, klebsiella pneumoniae, escherichia coli and pseudomonas aeruginosa, and can remove biofilms formed by staphylococcus aureus and enterococcus faecalis.

The application discloses a composition capable of effectively inhibiting the growth of Staphylococcus aureus biofilm. The application firstly optimizes the nitrogen source in the culture medium of Staphylococcus epidermidis CCSM0287 strain, fully explores the growth difference of Staphylococcus epidermidis under different culture media and culture conditions and the inhibition effect of the fermentation supernatant on Staphylococcus aureus biofilm, then compounds the fermentation supernatant of Staphylococcus epidermidis CCSM0287 obtained by using the optimized culture medium (the nitrogen source adopts tryptone + soybean peptone + fresh beef bone collagen peptide powder) with the fermentation supernatant of Lactobacillus paracasei S20, can obviously inhibit the growth of Staphylococcus aureus biofilm and destroy the surface structure of the Staphylococcus aureus biofilm, and can be applied in bacteriostatic products.

A bithionol derivative, and a preparation method therefor and a use thereof. The bithionol derivative is as represented by any one of chemical structural formulas I-1 to I-7. The bithionol derivative as represented by the structural formula exhibits better bacteriostatic activity against clinical isolates of gram-positive bacteria such as Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, and Staphylococcus epidermidis and the effect of inhibiting the formation of Staphylococcus aureus biofilms. As compared with bithionol and other bithionol derivatives, the bithionol derivative as represented by the structural formula has a lower inhibitory concentration, a better antibacterial effect, and potential application value in clinical antibacterial infection treatment.

The invention discloses a preparation method and application of a composite antibody IgY for preventing and treating acne, and belongs to the technical field of cosmetics. The preparation method comprises the following steps: (1) preparing immunogens: respectively mixing inactivated propionibacterium acnes liquid, staphylococcus epidermidis liquid, staphylococcus aureus liquid and escherichia coli liquid with an ISA 78 adjuvant to obtain the immunogens of the four bacteria; (2) immunizing: respectively injecting immunogens of the four bacteria to laying hens, and collecting to obtain immunized eggs of the four bacteria; and (3) collection and preparation of a composite antibody IgY: mixing immunized eggs of the four bacteria, separating yolk, and carrying out acid treatment and impurity removal to obtain the composite antibody IgY. The prepared composite antibody IgY is high in titer, has the effect of preventing and treating acne and acne infection, is high in safety and remarkable in curative effect, and provides a new treatment strategy for preventing and treating acne.

The invention discloses an antibacterial peptide as well as a composition and application thereof, an amino acid sequence of the antibacterial peptide is shown as a formula I. The antibacterial peptide has a good antibacterial effect on methicillin staphylococcus aureus MRSA, methicillin-sensitive staphylococcus aureus MSSA and methicillin-resistant staphylococcus epidermidis MRSE, and the antibacterial peptide has a good antibacterial effect on methicillin-sensitive staphylococcus aureus MRSA, methicillin-sensitive staphylococcus aureus MSSA and methicillin-resistant staphylococcus epidermidis MRSE. The antibacterial peptide and the pharmaceutical composition prepared by adding auxiliary materials are expected to be widely applied to preparation of drugs for controlling or preventing microbial infection.

The invention belongs to the technical field of probiotics, and particularly relates to plant lactobacillus with bacteriostatic activity and application of the plant lactobacillus. Wherein the plant lactobacillus with bacteriostatic activity is separated from the intestinal tract of a healthy human body, and the LV1000 fermentation filtrate freeze-dried powder is prepared through fermentation, centrifugation, filtration, ultrafiltration concentration and vacuum freeze-drying by taking inactivated staphylococcus epidermidis bacterial suspension as an inducer through a specific induction fermentation culture medium. Meanwhile, the freeze-dried powder is compounded with an embedding compound, galactooligosaccharide, beta-cyclodextrine, erythritol and the like, so that the fermented beverage capable of improving the intestinal microecology is prepared. The freeze-dried powder of the LV1000 fermentation filtrate can specifically inhibit enteropathogenic bacteria, the tea polyphenol in the embedded compound can further synergistically enhance the bacteriostatic action and exert the antioxidant effect, and the fermented beverage which is high in stability, fine and smooth in taste, free of refrigeration and capable of being directly drunk and improving the intestinal microecology is prepared.

To provide a composition effective for treating microbial skin infections, atopic dermatitis and the like.SOLUTION: Methods and compositions comprising hogocidin peptides (SH-lantibiotics), derivatives and variants are provided. Also provided are methods and compositions, including probiotic compositions, that utilize strains of Staphylococcus hominis and Staphylococcus epidermidis that produce hogocidin, hogocidin-like peptides, or other inhibitors of skin pathogens. Methods of treating microbial skin infections and atopic dermatitis are also provided.SELECTED DRAWING: Figure 1A-B

This invention belongs to the field of peptide drugs, specifically relating to an anti-drug-resistant bacterial peptide and its application in pharmaceutical manufacturing. Using Rink amide MBHA amino resin as a solid-phase support, the amino acid sequence of the template peptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 was modified, with amino acid residues 9I and 16F replaced by R8 and S5, respectively, to obtain the target stapling peptide PL-11. Compared to the template peptide PL-0, the stapling peptide PL-11 significantly enhances the antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, and Staphylococcus epidermidis.

Described is a method for treating or preventing an infection, such as an infection associated with Staphylococcus epidermidis such as a Health-Care Associated infection, a wound, a sore, an ulcer, a burn. The method includes applying a treatment preparation to a treatment site, the treatment preparation has a first component having a single amino acid, said single amino acid being leucine, and a second component having an active chlorine compound.

The invention provides an application of AZD-5991 in preparation of a medicine for resisting gram-positive bacterium infection, and the AZD-5991 has a CAS number of 2143061 to 81 to 6. According to the technical scheme, the novel medical application of the AZD-5991 is disclosed, the AZD-5991 shows antibacterial activity on various gram-positive bacteria including staphylococcus aureus, staphylococcus epidermidis, enterococcus faecalis and enterococcus faecium, and can inhibit formation of staphylococcus aureus and enterococcus faecalis biofilms, so that the AZD-5991 can be used for preparing the antibacterial agent for preventing and treating the AZD-5991. Bacteria of a staphylococcus aureus mature biofilm can be killed, and floating growth and biofilm formation of staphylococcus aureus can be inhibited by destroying cell membranes and targeting FabI.

This invention belongs to the field of peptide drugs, specifically relating to an anti-drug-resistant bacterial peptide and its application in pharmaceutical manufacturing. Using Rink amide MBHA amino resin as a solid-phase support, the amino acid sequence of the template peptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 was modified, with amino acid residues 6V and 13V replaced by R8 and S5, respectively, to obtain the target stapling peptide PL-10. Compared to the template peptide PL-0, the stapling peptide PL-10 significantly enhances the antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, and Staphylococcus epidermidis.

The invention discloses an application of a bupleurum chinense extract in preparation of an antibacterial product. According to the invention, it is found for the first time that various extracts (including aqueous extracts, ethanol extracts and extraction parts of different polar solvents) of bupleurum chinense have relatively good bacteriostatic activity on streptococcus pneumoniae, methicillin-resistant staphylococcus epidermidis, micrococcus luteus and enterococcus faecium. The antibacterial spectrums and effects of different extracts are different, and the research lays a solid foundation for developing novel anti-drug-resistant bacteria drugs and natural-source antibacterial products.

The present invention relates to the use of glycine or a composition comprising glycine for inhibiting the growth of restrictive malassezia when applied to the outer surface of the human body; wherein the composition comprises at least 0.04% glycine by weight of the composition. The invention also relates to the use of a glycine or a composition comprising a glycine in microbiome equilibrium on the surface, where the equilibrium means that the number of harmful microorganisms, which are restrictive malassezia, is selectively reduced without an effect of reducing the number of symbiotic microorganisms selected from the group consisting of Staphylococcus epidermidis and Propionibacterium acnes; wherein the composition comprises at least 0.04% glycine by weight of the composition.